BACKGROUND: We studied 265 people, among patients included in two hands, double-blind, comparative study of 1 year effects zoledronovoyi acid (ZOL) on ryzedronat (mean age 56 4years range 18-83years). (RIS) in patients or start (7 prednisolone. 5mg/day or equivalent) (prevention arm, n = 88) or continue to glucocorticoid therapy (treatment arm, n = 177). Methods: Patients received either an infusion of ZOL 5 mg or RIS 5 mg daily orally randomization, and Calcium (1000 mg) and vitamin D (400 1200IU).
The primary end point: the difference in percentage change from baseline bone mineral density (IPC) in the lumbar spine (LS) for 12 months. Secondary endpoints: percent change in IPC in the hip (TH) and femoral neck (FN), regarding changes in markers of bone turnover (beta-STH and P1NP), and overall security. CONCLUSIONS: During treatment subpopulation, ZOL increased LS OF 4. 7% to 3. 3% for rice and in TD percentage changes were 1. 8% to 0. 2%, respectively. In the prevention subpopulation, bone loss was prevented and treatment. In the LS percentage changes were 2. 5% to 0. 2% compared with ZOL RIS and TH percentage changes were 1. 1% to 0. 4%, respectively. ZOL significantly increased lumbar spine IPC a RIS at 12 lasix 30 mg months in the prevention of population (p = 0. 0024) and treatment subgroup (p = 0. 0232) in men. In the treatment subpopulation, ZOL showed significantly more reduction in serum relative beta-STH and P1NP rice in all time points. In the prevention subpopulation, ZOL significantly reduced beta-STH at all time points, and P1NP at Month 3 (p = 0. 0297) only. Both procedures were well tolerated by men, albeit with a higher frequency of influenza-like illness and hyperthermia events after infusion of ZOL. INTERPRETATION: annual ZOL preserves or increase in BMD over 1 year to more than the daily RIS in men receiving therapy with glucocorticoids. .
